Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens

Menopause

Volumn 6, Issue 2, 1999, Pages 134-137

  Mijatovic, Velja ^a   Van Der Mooren, Marius J ^a   Kenemans, Peter ^a,b   De Valk De Roo, Gerdien W ^a   Netelenbos, Coen ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Estrogen replacement therapy; Lipoprotein(A); Raloxifene

Indexed keywords

CONJUGATED ESTROGEN; RALOXIFENE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MENOPAUSE; NORMAL HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; LIPOPROTEIN(A); MIDDLE AGED; PIPERIDINES; POSTMENOPAUSE; RALOXIFENE; TREATMENT OUTCOME;

EID: 0033062084     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Scanu AM, Lawn RM, Berg K. Lipoprotein (a) and atherosclerosis. Ann Intern Med 1991;115:209-18.
2. Mahler VMG, Brown BG. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol 1995;6:229-35.
3. Schumacher M, Weigert S, Wood WG. Do gonadotropins influence serum lipoprotein (a) concentrations? - observations on children, adolescents and adults. Eur J Clin Chem Clin Biochem 1996;34:909-14.
4. Brushi F, Meschia M, Soma M, Perotti D, Paoletti R, Crosignani PG. Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy. Obstet Gynecol 1996;88:950-4.
5. Berglund L. Diet and drug therapy for lipoprotein (a). Curr Opin Lipidol 1995;6:48-56.
6. Van der Mooren MJ, Demacker PNM, Thomas CMG, Borm GF, Rolland R. A 2-year study on the beneficial effects of 17(-estradiol-dydrogesterone therapy on serum lipoproteins and lipoprotein(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol Reprod Biol 1993;52:117-23.
7. Soma MR, Osnago-Gadda I, Paoletti R, et al. 1993 The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 13:1462-8.
8. Taskinen MR, Puolakka J, Pyorala T, et al. Hormone replacement therapy lowers plasma lipoprotein(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol 1996;16:1215-21.
9. Mijatovic V, Kenemans P, Netelenbos JC, et al. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein (a) concentrations in healthy postmenopausal women. J Clin Endocrinol Metab 1997;82:3543-7.
10. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
11. Pines A, Mijatovic V, Van der Mooren MJ, Kenemans P. Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. Eur J Obstet Gynecol Reprod Biol 1997;71:193-7.
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
13. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY 139481) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1995;93:63-9.
14. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY 139481) HCL: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Mineral Res 1996;11:835-42.
15. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
16. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
17. Kauffman R, Bryant H. Selective estrogen receptor modulators. DN&P 1995;8:531-9.
18. McDonald CC, Alexander FE, Thyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 1995;311:977-80.
19. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J 1991;303:435-7.
20. Crook D, Sidhu M, Seed M, O'Donnell M, Stevenson JC. Lipoprotein (a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992;92:41-7.
21. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein (a) concentrations in healthy postmenopausal women. Artherioscler Thromb 1994;4:1586-93.
22. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721-6.
23. Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P. Randomised, double-blind, placebo-controlled study on the effects of raloxifene and conjugated equine estrogen on plasma homocysteine in healthy postmenopausal women. Fertil Steril 1998;70:1085-9.
24. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 1990;85:1542-7.
25. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein (a) concentrations with apolipoprotein (a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994;93:2758-63.